Fig. 3
Post-vaccine neutralisation of live Wuhan virus and Delta variant. A (i) Maximum neutralisation of live virus using post-vaccine sera from healthy donors (HD; n = 94) and patients with CLL (n = 94) (p < 0.0001 Kruskal–Wallis). (ii) Maximum neutralisation in 53 CLL patients with a positive spike-specific antibody response following second vaccine (p < 0.0001). (iii) Maximum neutralisation using post-vaccine sera in HD and patients with serological evidence of previous natural infection with SARS-CoV-2. B Correlation between ND50 value against Wuhan virus or delta variant and spike-specific antibody titre in HD (Wuhan r = 0.80 and Delta r = 0.77; p < 0.0001) and CLL patients with a positive antibody response (Wuhan r = 0.60 and for Delta r = 0.61; p = < 0.0001)